The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID
Krumholz H, Sawano M, Bhattacharjee B, Caraballo C, Khera R, Li S, Herrin J, Coppi A, Holub J, Henriquez Y, Johnson M, Goddard T, Rocco E, Hummel A, Al Mouslmani M, Putrino D, Carr K, Carvajal-Gonzalez S, Charnas L, De Jesus M, Ziegler F, Iwasaki A. The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID. The American Journal Of Medicine 2024 PMID: 38735354, DOI: 10.1016/j.amjmed.2024.04.030.Peer-Reviewed Original ResearchLC trialPROMIS-29Participants' homesTargeting viral persistencePlacebo-controlled trialDouble-blind studyElectronic health recordsCore Outcome MeasuresLong COVIDEQ-5D-5LRepeated measures analysisEvidence-based treatmentsPhase 2Double-blindParticipant-centred approachStudy drugPrimary endpointSecondary endpointsCommunity-dwellingHealth recordsHealthcare utilizationContiguous US statesViral persistencePatient groupDrug treatmentImpaired mobility and MRI markers of vascular brain injury: Atherosclerosis Risk in Communities and UK Biobank studies
Sharma R, de Havenon A, Rivier C, Payabvash S, Forman R, Krumholz H, Falcone G, Sheth K, Kernan W. Impaired mobility and MRI markers of vascular brain injury: Atherosclerosis Risk in Communities and UK Biobank studies. BMJ Neurology Open 2024, 6: e000501. PMID: 38288313, PMCID: PMC10823923, DOI: 10.1136/bmjno-2023-000501.Peer-Reviewed Original ResearchVascular brain injurySlow walkingAtherosclerosis RiskMobility impairmentsAssociated with mobility impairmentImpaired mobilityUK Biobank (UKBStroke-free cohortMarkers of vascular brain injuryAdjusted multivariate logistic regression analysisGait dataMultivariate logistic regression analysisCommunity-dwellingLogistic regression analysisBrain injuryARICUKBInclusion criteriaStudy cohortWalkingClinical strokeRegression analysisImpaired outcomeMRI markersStudy background